Nektar Therapeutics
Nektar Therapeutics (NKTR) announced the publication of Phase 1 clinical data for its immuno-oncology candidate, bempegaldesleukin (BEMPEG: NKTR-214) + nivolumab, in Cancer Discovery - a journal of the American Association for Cancer Research.
Previously published Phase 1 data in Cancer Discovery informed that BEMPEG administered as monotherapy . . .
This content is for paid subscribers.
Today’s Highlights
May 22, 2020
